Evidence map›Paper›PMID 31725776›Full record

ArticlePloS one2019

Restrained expansion of the recall germinal center response as biomarker of protection for influenza vaccination in mice.

Laurens P Kil, Joost Vaneman, Joan E M van der Lubbe, Dominika Czapska-Casey, Jeroen T B M Tolboom, Ramon Roozendaal, Roland C Zahn, Harmjan Kuipers, Laura Solforosi

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Laurens P KilJanssen Vaccines & Prevention B.V., Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
Joost VanemanJanssen Vaccines & Prevention B.V., Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
Joan E M van der LubbeJanssen Vaccines & Prevention B.V., Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
Dominika Czapska-CaseyJanssen Vaccines & Prevention B.V., Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
Jeroen T B M TolboomJanssen Vaccines & Prevention B.V., Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
Ramon RoozendaalJanssen Vaccines & Prevention B.V., Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
Roland C ZahnJanssen Vaccines & Prevention B.V., Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
Harmjan KuipersJanssen Vaccines & Prevention B.V., Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
Laura SolforosiJanssen Vaccines & Prevention B.V., Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.ORCID 0000-0003-3786-6468
Janssen (Netherlands) · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Correlates of protection (CoP) are invaluable for iterative vaccine design studies, especially in pursuit of complex vaccines such as a universal influenza vaccine (UFV) where a single antigen is optimized to elicit broad protection against many viral antigenic variants. Since broadly protective antibodies against influenza virus often exhibit mutational evidence of prolonged diversification, we studied germinal center (GC) kinetics in hemagglutinin (HA) immunized mice. Here we report that as early as 4 days after secondary immunization, the expansion of HA-specific GC B cells inversely correlated to protection against influenza virus challenge, induced by the antigen. In contrast, follicular T helper (TFH) cells did not expand differently after boost vaccination, suggestive of a B-cell intrinsic difference in activation and differentiation inferred by protective antigen properties. Importantly, differences in antigen dose only affected GC B-cell frequencies after primary immunization. The absence of accompanying differences in total anti-HA or epitope-specific antibody levels induced by vaccines of different efficacy suggests that the GC B-cell response upon revaccination represents an early and unique marker of protection that may significantly accelerate the pre-clinical phase of vaccine development.

Indexed as

BiomarkersImmunologic MemoryAnimalsAntibodies, NeutralizingAntibodies, ViralDisease Models, AnimalGerminal CenterHemagglutinin Glycoproteins, Influenza VirusImmunizationInfluenza VaccinesMiceOrthomyxoviridae InfectionsAntibodies, NeutralizingAntibodies, ViralBiomarkersHemagglutinin Glycoproteins, Influenza VirusInfluenza Vaccines

Identifiers

PMID31725776
PMCPMC6855462
OpenAlexW2989254719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.